 |
Effect
of intensive glucose lowering treatment on all cause mortality,
cardiovascular death, and microvascular events in type 2 diabetes |
| |
The overall results of this meta-analysis show
limited benefits of intensive glucose lowering treatment on all
cause mortality and deaths from cardiovascular causes (BMJ) |
| |
|
|
Achieved
Levels of HbA1c and Likelihood of Hospital Admission in People
With Type 1 Diabetes in the Scottish Population |
| |
People with type 1 diabetes with highest and
lowest mean HbA1c values were associated with increased odds of
admission - Achieved Levels of HbA1c and Likelihood of Hospital
Admission in People With Type 1 Diabetes in the Scottish Population
(Diabetes Care) |
| |
|
|
Number
of HbA1c tests unrelated to quality of diabetes control: An electronic
medical record data linkage study |
| |
A unique primary care electronic medical record-health
administrative database linkage found no clinically meaningful
relationship between control (HbA1c value) and number of tests
performed, casting doubt on the usefulness in diabetes performance
and quality of care assessment (Diabetes Research and Clinical
Practice) |
| |
|
|
Metformin
improves the hepatic insulin resistance index independently of
anthropometric changes |
| |
Metformin improves HIRI independently of anthropometric
changes. In persons with elevated HIRI levels, metformin may be
considered among the treatment options (Endocrine Practice) |
| |
|
|
Fasting
insulin reflects heterogeneous physiological processes: role
of insulin clearance |
| |
Fasting insulin is a complex phenotype influenced
by several independent processes, each of which might have its
own environmental and genetic determinants. One of the most associated
traits was insulin clearance, which has implications for studies
that have used fasting insulin as a surrogate for insulin resistance
(American Physiological Society) |
| |
|
|
European
Medicines Agency recommends new contra-indications and warnings
for pioglitazone to reduce small increased risk of bladder cancer |
| |
The CHMP also concluded that the small increased
risk could be reduced by appropriate patient selection and exclusion,
including a requirement for periodic review of the efficacy and
safety of the individual patient’s treatment (European Medicines Agency) |
| |
|
|
FDA
Advisory Committee Makes Recommendation on Investigational Compound
Dapagliflozin |
| |
On the question: "Do
the efficacy and safety data provide substantial evidence to support
approval of dapagliflozin as an adjunct to diet and exercise to
improve glycemic control in adults with type 2 diabetes mellitus?" the Advisory Committee voted 6 yes and 9 no (World Pharma News) |
| |
|
|
Takeda
resubmits NDA for new diabetes drug alogliptin |
| |
Akeda Pharmaceutical Co has resubmitted two
New Drug Applications to regulators in the USA for its investigational
type 2 diabetes therapy alogliptin and the fixed-dose combination
of the drug and the Japanese drugmaker's Actos - pioglitazone (PharmaTimes) |
| |
|
|
Bydureon
Reply Submitted to FDA |
| |
The reply submission includes results from the
recently completed thorough QT (tQT) study, which showed that exenatide,
at and above therapeutic levels, did not prolong the corrected
QT interval in healthy individuals as defined by the FDA's published
guidance (PharmaLive) |
| |
|
|
Bardoxolone
Methyl and Kidney Function in CKD with Type 2 Diabetes |
| |
Bardoxolone methyl was associated with improvement
in the estimated GFR in patients with advanced CKD and type 2 diabetes
at 24 weeks. The improvement persisted at 52 weeks, suggesting
that bardoxolone methyl may have promise for the treatment of CKD
(NEJM) |
| |
|
|
Isis
Initiates Phase 1 Study of ISIS-PTP1BRx to Treat Type 2 Diabetes |
| |
ISIS-PTP1BRx is designed to increase the body's
sensitivity to the natural hormone insulin, resulting in better
glucose control for patients with type 2 diabetes (ISIS Pharmaceuticals) |
| |
|
